Ardelyx, Inc. (ARDX): Cost of Revenue
$39.54M
Year ended 2025-12-31
$25.40M
Trailing 12 months to 2026-06-30
+112.6%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $39.54M | -21.8% | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | $50.56M | +184.1% | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | $17.80M | +332.2% | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | $4.12M | +311.7% | 2025-02-20, From 2022-01-01 |
| 2021-12-31 | $1.00M | +589.7% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $145.0K | -75.8% | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | $600.0K | +28.8% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $466.0K | -94.5% | 2021-03-08, From 2018-01-01 |
| 2017-12-31 | $8.40M | n/a | 2020-03-06, From 2017-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $39.54M | -21.8% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $124.03M | -11.8% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $36.70M | +91.8% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $190.52M | +29.5% |
| MannKind Corp (MNKD) | 2025-12-31 | $26.80M | +53.8% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $132.42M | +2.1% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $10.34M | +33.5% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $20.96M | +440.5% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $22.09M | +628.0% |
Compare ARDX, SVA, ARQT, ZLAB side by side · Screen every company in Pharmaceutical Preparations ↗